Related Experiment Video

Updated: Jul 8, 2026

Utilizing Murine Inducible Telomerase Alleles in the Studies of Tissue Degeneration/Regeneration and Cancer
08:34

Utilizing Murine Inducible Telomerase Alleles in the Studies of Tissue Degeneration/Regeneration and Cancer

Published on: April 13, 2015

Characterization and antitumor activity of triethylene tetramine, a novel telomerase inhibitor

Jianhui Liu, Lixia Guo, Fei Yin

    Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie
    |January 1, 2008
    PubMed

    Insights

    Triethylene tetramine (TETA) shows antitumor potential by inhibiting telomerase activity. While TETA alone has limited tumor cell growth inhibition, it significantly enhances the efficacy of conventional chemotherapy drugs.

    Area of Science:

    • Biochemistry
    • Molecular Biology
    • Pharmacology

    Background:

    • Triethylene tetramine (TETA) is recognized as a G-quadruplex ligand with diverse biological activities, including telomerase inhibition and induction of tumor cell senescence.
    • Investigated the tumor-inhibiting activity and mechanism of TETA in HeLa and MCF-7 cancer cell lines, as well as in a mouse model with S180 tumors.

    Discussion:

    • TETA demonstrated telomerase inhibition by reducing the expression of human telomerase reverse transcriptase (hTERT).
    • Low concentrations of TETA exhibited minimal direct tumor cell growth inhibition in short-term cultures.
    • TETA significantly potentiated the antitumor effects of established chemotherapeutic agents both in vitro and in vivo.

    Key Insights:

    • TETA effectively inhibits telomerase, a key target in cancer therapy.
    • TETA acts as a sensitizer, enhancing the effectiveness of traditional antitumor drugs.
    • The compound's mechanism involves downregulating hTERT expression.

    Outlook:

    • Further research into TETA as a chemosensitizer could lead to novel combination therapies.
    • Exploring TETA's synergistic effects with various anticancer drugs may optimize treatment strategies.
    • Investigating the long-term effects and safety profile of TETA in combination therapies is warranted.

    More Related Videos

    In vitro Reconstitution of the Active T. castaneum Telomerase09:25

    In vitro Reconstitution of the Active T. castaneum Telomerase

    Published on: July 14, 2011

    Related Concept Videos

    Telomeres and Telomerase02:41

    Telomeres and Telomerase

    In eukaryotic DNA replication, a single-stranded DNA fragment remains at the end of a chromosome after the removal of the final primer. This section of DNA cannot be replicated in the same manner as the rest of the strand because there is no 3’ end to which the newly synthesized DNA can attach. This non-replicated fragment results in gradual loss of the chromosomal DNA during each cell duplication. Additionally, it can induce a DNA damage response by enzymes that recognize single-stranded DNA.
    Telomeres and Telomerase02:41

    Telomeres and Telomerase

    In eukaryotic DNA replication, a single-stranded DNA fragment remains at the end of a chromosome after the removal of the final primer. This section of DNA cannot be replicated in the same manner as the rest of the strand because there is no 3’ end to which the newly synthesized DNA can attach. This non-replicated fragment results in gradual loss of the chromosomal DNA during each cell duplication. Additionally, it can induce a DNA damage response by enzymes that recognize single-stranded DNA.
    Replicative Cell Senescence02:15

    Replicative Cell Senescence

    Replicative cell senescence is a property of cells that allows them to divide a finite number of times throughout the organism's lifespan while preventing excessive proliferation. Replicative senescence is associated with the gradual loss of the telomere — short, repetitive DNA sequences found at the end of the chromosomes. Telomeres are bound by a group of proteins to form a protective cap on the ends of chromosomes. Embryonic stem cells express telomerase — an enzyme that adds the telomeric...
    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against specific...
    Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

    Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

    Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...